dimethyl celecoxib (DMC), a close derivative of celecoxib, has also been reported to have
anticancer effects. However, the effects and underlying molecular mechanisms of DMC with …

OSU-03012 is a celecoxib derivative devoid of cyclooxygenase-2 inhibitory activity. It was
previously reported to inhibit the growth of some tumor cells through the AKT-signaling …

Aim: To investigate the mechanisms underlying the anticancer effect of celecoxib on
nasopharyngeal carcinoma (NPC). Methods: NPC cell lines, HNE1 and CNE1-LMP1, were …

Gastric cancer, one of the most common malignancies worldwide, typically has a poor
prognosis and poor survival rate. Previous studies have investigated the chemopreventive …

Celecoxib is a potent nonsteroid antiinflammatory drug (NSAID) that has shown great
promise in cancer chemoprevention and treatment. The tumor suppression activity of …

Abstract Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated
to exert antitumor activity in a variety of cancer cells. The underlying mechanism involves …

Previously, we showed that treatment with celecoxib obviously inhibited proliferation of
nasopharyngeal carcinoma (NPC) cell lines in a dose-dependent manner. However, the …

Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, can elicit anti-tumor effects in various
malignancies. Here, we sought to clarify the role of autophagy in celecoxib-induced …

Background: Clinical studies have shown that celecoxib can significantly inhibit the
development of tumors, and basic experiments and in vitro experiments also provide a …

Dimethyl-celecoxib (DMC) is a close structural analog of the selective COX-2 inhibitor
celecoxib that lacks COX-2-inhibitory function. Thus, DMC is a promising drug for anti-tumor …